comparemela.com
Latest Breaking News On - Roceeds slno us8342033094 - Page 1 : comparemela.com
Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.
Soleno Therapeutics, Inc. announced it has entered into a securities purchase agreement for a private placement of 22,600,000 common shares at a price of $2.65 per share for gross proceeds $59,890,000. |
Manish-bhatnagar
James-mackaness
Soleno-therapeutics-inc
Blackwell-partners
Vivo-capital
Drug-administration
Nantahala-capital-management
Soleno-therapeutics
Abingworth-bioventures
Nantahala-capital-partners
Pinehurst-partners
Nc-stock-exchange
vimarsana © 2020. All Rights Reserved.